Beijing Innovic Pharmaceutical Technology

Innovic Pharmaceutical is a clinical-stage biotechnology company based in Beijing, China, focused on the discovery and development of innovative small molecule drugs for oncology. The company leverages its expertise in the DNA Damage Response (DDR) and the ubiquitin-proteasome system to target cancers with high unmet medical needs. Its lead candidate, IVC1022, is a highly selective USP1 inhibitor currently in Phase 1 clinical trials for the treatment of advanced solid tumors, particularly those with BRCA mutations. Innovic aims to overcome resistance to current therapies, such as PARP inhibitors, through precision medicine. The company is backed by prominent life science investors, including Qiming Venture Partners and Lilly Asia Ventures.